All data are based on the daily closing price as of July 18, 2024
g

GC Biopharma

006280.KO
92.44 USD
0.34
+0.37%

Overview

Last close
92.44 usd
Market cap
1.06B usd
52 week high
105.76 usd
52 week low
70.06 usd
Target price
104.4 usd

Valuation

P/E
N/A
Forward P/E
17.5439
Price/Sales
0.7767
Price/Book Value
0.9717
Enterprise Value
1.73B usd
EV/Revenue
1.1877
EV/EBITDA
25.01

Key financials

Revenue TTM
1.18B usd
Gross Profit TTM
375.56M usd
EBITDA TTM
79.63M usd
Earnings per Share
N/A usd
Dividend
1.08 usd
Total assets
1.99B usd
Net debt
N/A usd

About

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; Varicella Vaccine-GCC inj. for prophylaxis of varicella; and Varicella-Zoster Immune Globulin-GCC inj. for passive immunity to susceptible immunodeficient children exposed to varicella. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. is a subsidiary of Green Cross Holdings Corporation.
  • Symbol
    006280.KO
  • Exchange
    KO
  • Isin
    KR7006280002
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Il-Sup Huh Ph.D.
  • Headquarter
    Yongin-Si
  • Web site
    https://www.globalgreencross.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top